Early Phase 1
Completed N=40
Using an Internet Study to Improve Adherence for Psoriasis Patients
Psoriasis
Source: ClinicalTrials.gov NCT01802580 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Nov 2019
Primary outcomePrimary: Measured MEMS Adherence- Number of Days With a Correct Number of Doses Taken — 15.14; 20.22 Days
Summary
To evaluate whether participation in an Internet-based intervention helps improve short-term and long-term psoriasis treatment outcomes, in particular, adherence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Measured MEMS Adherence- Number of Days With a Correct Number of Doses Taken |
15.14; 20.22 | — |
| SECONDARY Mean of Days Per Week Medication Was Taken - Internet Survey |
5.38 | — |
| SECONDARY Disease Severity With PASI |
6.0; 4.31; 3.41; 2.94 | — |
| SECONDARY Disease Severity With IGA Assessment |
2.6; 2.5; 2.5; 2.3 | — |
Eligibility Criteria
Inclusion Criteria
- Any male or female 18 years or older of age with a diagnosis of mild to moderate psoriasis by a dermatologist will be eligible for participation.
- Less than 20% of body surface involvement for psoriasis.
- Subject is capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed.
- The subject is able to complete the study and comply with study instructions, including attending all study visits.
- In general good health with no other skin disease, disease state or physical condition which would impair evaluation of psoriasis or which would increase health risk by study participation
Exclusion Criteria
- Individuals younger than 18 years of age.
- Known allergy or sensitivity to topical fluocinonide.
- Inability to complete all study-related visits, or inability to complete the Internet survey due to inadequate Internet access.
- Introduction of any other prescription medication, topical or systemic, for psoriasis while participating in the study. Subjects who are on systemic anti-inflammatory treatments for psoriasis must be on a stable dose for at least 3 months prior to enrollment.
- Any skin condition or disease that may require concurrent therapy or may confound evaluations
- Current enrollment in any research study involving an investigational drug
Data sourced from ClinicalTrials.gov (NCT01802580). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.